News and Media

UPMPHARMACEUTICALS®,INC. ANNOUNCES API DIRECT-FILL CAPABILITIES

Baltimore, MD, August 21, 2007 – UPM Pharmaceuticals®, Inc., reports extraordinary interest in it's newly purchased XcelodoseTM 600 System since installation and qualification earlier this year. This state-of-the-art equipment reduces early stage formulation activities because capsules can be filled solely with the drug substance. The addition of the XcelodoseTM 600 System to UPM’s expanding range of capabilities will allow the company to offer clients a way to shorten their time through the drug development process. The Xcelodse 600 is fully automated avoiding the inaccuracies associated with hand-filling, and can fill doses as low as 100 ug. This technology reduces the time taken to reach the ‘first in humans’ clinical trial decision point, which allows an increase in throughput of candidate compounds for development.

 

UPMPharmaceuticals®, Inc. is a Baltimore-based, independent pharmaceutical company that provides product development and manufacturing services to pharmaceutical and biotechnology companies. UPM’s scientists use state-of-the-art technological approaches to solve challenging early stage pharmaceutical product design and formulation problems. Their services include: formulation development and optimization; cGMP manufacture of clinical trial materials; blinding of clinical supplies; analytical methods development and validation; ICH Stability studies; scale-up and technology transfer; and regulatory support. Their clients represent both small and large companies within the pharmaceutical and biotechnology industries.

For more information, visit www.upm-inc.com and the UPMPharmaceuticals®, Inc., exhibit (#1501) at the AAPS Annual Meeting in San Diego, November 11-15, 2007.

 

Contact:
Fran Spaven: 410.843.3719
Sara Mathew: 425.322.5866
UPM Pharmaceuticals®, Inc.
6200 Seaforth Street, Baltimore,MD 21224
Phone: 410.843.3700